SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Pharmaceuticals informs about allotment of bonus equity shares

19 Sep 2018 Evaluate

Pursuant to the approval granted by the shareholders vide postal ballot on 5th September , 2018, Glaxosmithkline Pharmaceuticals has informed that as authorized by Board the meeting of Managing Director, Whole-time Director and Company Secretary held on 14th September 2018, has approved the allotment of 8,47,03,017 fully paid-up bonus equity shares to the existing shareholders in the ratio of one bonus equity share of face value Re 10 each credited as fully paid up for every one equity shares of face value Re 10 each held on the Record date viz. 13th September 2018. The post issued paid up capital of the Company is now Rs 169,40,60,340.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2451.80 32.70 (1.35%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×